Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -348.00 -4.87% 6,794.00 6,782.00 6,787.00 7,058.00 6,689.00 7,000.00 5,236,989 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,386.4 1,167.2 77.7 84.6 89,122

AstraZeneca PLC AstraZeneca divests Seroquel rights: US and Canada

03/12/2019 7:00am

UK Regulatory (RNS & others)


Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Nov 2019 to Feb 2020

Click Here for more Astrazeneca Charts.

TIDMAZN

RNS Number : 4612V

AstraZeneca PLC

03 December 2019

3 December 2019 07:00 GMT

AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada

Sale to Cheplapharm supports AstraZeneca's focus on main therapy areas

AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas. Cheplapharm recently agreed to acquire the commercial rights to Seroquel and Seroquel XR in most European markets and Russia from AstraZeneca and this new agreement will help ensure continued patient access to this important established medicine in North America as well."

AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period.

Financial considerations

Cheplapharm will make an upfront payment of $35m to AstraZeneca and may also make future sales-contingent payments of up to $6m. Income arising from the upfront and future payments will be reported in AstraZeneca's financial statements within Other Operating Income & Expense. In 2018, Seroquel generated sales of $36m in the markets covered by this agreement, while Seroquel XR generated $79m. The agreement does not impact the Company's financial guidance for 2019. As there were no closing conditions to the divestment, the agreement became effective upon signing.

Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as at 31 December 2018 was nil. In the year to 31 December 2018, the aggregate profit before tax attributable to Seroquel and Seroquel XR in the relevant territories were $108m. The consideration will be paid in cash and the proceeds used for general corporate purposes.

About Seroquel

Seroquel and Seroquel XR are atypical anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.

AstraZeneca previously divested the rights to Seroquel and Seroquel XR in the UK, Japan and other major international markets. AstraZeneca also agreed to divest the rights to the medicines in Europe (excluding the UK) and Russia to Cheplapharm earlier in 2019, a transaction that is expected to complete in the fourth quarter of 2019, subject to customary closing conditions and regulatory clearances.

About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 
 Media Relations 
 Gonzalo Viña                                                                                    +44 203 749 5916 
 Rob Skelding                           Oncology                                                      +44 203 749 5821 
 Rebecca Einhorn                        Oncology                                                       +1 301 518 4122 
 Matt Kent                              BioPharmaceuticals                                            +44 203 749 5906 
 Jennifer Hursit                        Other                                                         +44 203 749 5762 
 Christina Malmberg Hägerstrand    Sweden                                                        +46 8 552 53 106 
 Michele Meixell                        US                                                             +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                                                  +44 203 749 5712 
 Henry Wheeler                          Oncology                                                      +44 203 749 5797 
 Christer Gruvris                       BioPharmaceuticals (Cardiovascular, Metabolism)               +44 203 749 5711 
                                        BioPharmaceuticals (Renal) Environmental, Social and 
 Nick Stone                              Governance                                                   +44 203 749 5716 
                                        BioPharmaceuticals (Respiratory) 
 Josie Afolabi                           Other medicines                                              +44 203 749 5631 
                                        Finance 
 Craig Marks                             Fixed income                                                 +44 7881 615 764 
                                        Corporate access 
 Jennifer Kretzmann                      Retail investors                                             +44 203 749 5824 
 US toll-free                                                                                         +1 866 381 72 77 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCQXLBBKLFBFBE

(END) Dow Jones Newswires

December 03, 2019 02:00 ET (07:00 GMT)

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200229 10:58:37